Cardiovascular Risk Scores among Asymptomatic Adults with Haemophilia.

Autor:	Camelo RM; Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG - Brasil.; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil.; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden - Países Baixos., Caram-Deelder C; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden - Países Baixos.; Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden - Países Baixos., Duarte BP; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil., Moura MCB; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil., Costa NCM; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil., Costa IM; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil., Vanderlei AM; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil., Guimarães TMR; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife, PE - Brasil.; Faculdade de Enfermagem Nossa Senhora das Graças, Universidade de Pernambuco, Recife, PE - Brasil., Gouw S; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden - Países Baixos.; Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam,Amsterdã - Países Baixos., Rezende SM; Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG - Brasil., Bom JV; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden - Países Baixos.; Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden - Países Baixos.
Jazyk:	English; Portuguese
Zdroj:	Arquivos brasileiros de cardiologia [Arq Bras Cardiol] 2023 Sep 18; Vol. 120 (9), pp. e20230004. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).
DOI:	10.36660/abc.20230004
Abstrakt:	Background: The mortality rate of Brazilian people with haemophilia (PwH) is decreasing, but the relative incidence of deaths associated with cardiovascular disease (CVD) is increasing. Objectives: We aimed to describe the CVD risk score of PwH according to Pooled Cohort Equations Risk (PCER) Calculator tool and its treatment recommendations. We also compared the PCER estimates with the respective Framingham Risk Score (FRS). Methods: This cross-sectional study included male PwH ≥ 40 years treated at the Comprehensive Haemophilia Treatment Centre of Pernambuco (Recife/Brazil). PwH with a previous CVD event or a low-density lipid cholesterol ≥ 5.0 mmol/L were excluded. Interviews, medical file reviews, and blood tests were performed. The PCER tool was used to estimate the CVD risk and compare it with the respective FRS. A p-value < 0.05 was accepted as statistically significant. Results: Thirty PwH were included. Median age was 51.5 [interquartile range-IQR; 46.0-59.5] years. The prevalence of obesity, systemic arterial hypertension, diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, and hypoHDLaemia were 20%, 67%, 24%, 14%, 47%, and 23%, respectively. The median PCER score was 6.9% [IQR; 3.1-13.2], with 50% having a high risk (PCER ≥ 7.5%). Statin use was suggested for 54% of PwH. Blood pressure was poorly controlled in 47% of PwH. The agreement between PCER and FRS was 80% (κ = 0.60; p = 0.001). Conclusions: Half of the male people with haemophilia aged 40 years or older had a 10-year high risk of developing CVD with strong recommendations to improve control of dyslipidaemia and blood pressure.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu